Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
Abstract Peroxiredoxin 6 (PRDX6) is one of the Peroxiredoxin family members with only 1-Cys, using glutathione as the electron donor to reduce peroxides in cells. PRDX6 has been frequently studied and its expression was associated with poor prognosis in many tumors. However, the expression of PRDX6...
Saved in:
Main Authors: | Dandan Gao, Yang Lv, Fei Hong, Dong Wu, Ting Wang, Gongzhizi Gao, Zujie Lin, Ruoyu Yang, Jinsong Hu, Aili He, Pengyu Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-84021-y |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Boanmycin overcomes bortezomib resistance by inducing DNA damage and endoplasmic reticulum functional impairment in multiple myeloma
by: Jin-Xing Wang, et al.
Published: (2025-01-01) -
Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01) -
Guillain-Barré syndrome in patients with multiple myeloma: three cases report and literature review
by: Zhichao Li, et al.
Published: (2025-01-01) -
Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
by: Eva Plakoula, et al.
Published: (2025-01-01) -
Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)